相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The PARTNER 3 trial demonstrates that transcatheter aortic valve replacement (TAVR) provides similar clinical outcomes to surgery at 7 years in low-risk patients with severe aortic stenosis. - Bioprosthetic valve failure rates were comparable between treatments, with 6.9% for TAVR and 7.3% for surgery, addressing durability concerns. - The study found no significant difference in the composite endpoint of death, stroke, or rehospitalization, with rates of 34.6% for TAVR versus 37.2% for surgery. - These findings support TAVR as a viable long-term treatment option for low-risk patients, though valve thrombosis rates remained higher with TAVR at 2.8% versus 0.5% for surgery.
- Edwards Lifesciences' SAPIEN 3 platform has received FDA approval for treating asymptomatic patients with severe aortic stenosis, marking the first such approval for transcatheter aortic valve replacement in this patient population. - The groundbreaking EARLY TAVR trial demonstrated superior outcomes with TAVR compared to watchful waiting, with 26.8% versus 45.3% of patients experiencing death, stroke, or unplanned cardiovascular hospitalization over a median 3.8-year follow-up. - This approval challenges the current "watchful waiting" approach to asymptomatic severe aortic stenosis, potentially transforming treatment pathways as symptoms can develop suddenly and unpredictably in these patients.
